Mcl-1 downregulation in melanoma cells was also seen in response to some other pro-apoptotic strategies, including treatment with TRAIL (TNF-related apoptosis inducing ligand) in combinations with kinase inhibitors such as vemurafenib, indirubin, or BMS-345541 [20,87,88]. This evidence concerns the gene MCL1 and melanoma.